The value of inhibitors of factor Xa for the treatment of pulmonary embolism.

@article{Prandoni2014TheVO,
  title={The value of inhibitors of factor Xa for the treatment of pulmonary embolism.},
  author={Paolo Prandoni and Sally N. Temraz and Sofia Barbar and Raffaele Pesavento and Ali Asghar Taher},
  journal={Internal and emergency medicine},
  year={2014},
  volume={9 6},
  pages={617-22}
}
The introduction of factor Xa inhibitors advocated the initiation of clinical trials that addressed the value of anticoagulation in patients with hemodynamically stable primary pulmonary embolism (PE). In the Matisse trial in patients with PE, fondaparinux administered at therapeutic doses followed by vitamin K antagonists (VKA) has shown a comparable efficacy and safety profile to that seen with intravenous adjusted-dose unfractionated heparin/VKA. A long-acting derivative of fondaparinux… CONTINUE READING

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…